Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Limited was incorporated on 16th April 2019 as Asston Pharmaceutical Pvt. Limited to contract produce pharmaceutical products for export market. Later on 1st April 2024 Company acquired Ferron Lifecare Private Limited specializing into nutraceuticals business and produced nutraceutical products at their Ambarnath facility. Ferron Lifecare Private Limited incorporated on 30th January 2020 was promoted by Dr. Ashish Sakalkar and Mr. Sachin Badakh. Finally Asston Pharmaceuticals Private Limited was converted from a Private Limited into a Public Limited Company in the name of Asston Pharmaceuticals Limited on 29th August 2024 and received FDA approval for its Ambarnath facility on 2nd December 2024 to produce pharmaceutical products.Company is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets. It operates under brand Asston. Presently Company is involved in the business of manufacturing and marketing of Tablets Capsules Oral Liquid External Preparations Ointment Cream Gel and Lotion and Oral Powder Sachet Dry Syrup etc. Companys operations are supported by experienced founders with expertise in managing supply chains and maintaining product quality. Currently Company has its production plant at Ambernath Maharashtra for producing generic medicines in the tablet form and nutraceutical medicines in the tablet form syrup and sachet form. Facility has total production capacity of up to around 89 crore tablets per month. Further it produces an average of 56 crore tablets per month with production capacity varying based on the weight of medicines. Higherweight medicines result in lower production quantities and vice versa. The syrup production capacity for nutraceuticals is approximately 37.5 kiloliters per month while sachet production capacity ranges from 30 to 40 lakh sachets per month depending on the powder weight per sachet. The facility is certified by relevant authorities and undergoes periodic audits by state and central FDA authorities. Company engages contract manufacturers to produce generic medicines and antibiotics in various forms including tablets sachets syrups and capsules.Company is planning an Initial Public Issue of 2241600 Equity Shares of face value of Rs. 10/ through Fresh Issue..